hemagglutination inhibition tests

Summary

Summary: Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination.

Top Publications

  1. ncbi A novel influenza A (H1N1) vaccine in various age groups
    Feng Cai Zhu
    Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
    N Engl J Med 361:2414-23. 2009
  2. ncbi Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials
    Eric Plennevaux
    Clinical Development Department, Sanofi Pasteur, Lyon, France
    Lancet 375:41-8. 2010
  3. pmc Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls
    Ron A M Fouchier
    Dept of Virology, Erasmus Medical Center, P O Box 1738, 3000 DR Rotterdam, The Netherlands
    J Virol 79:2814-22. 2005
  4. ncbi Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine
    Tristan W Clark
    Infectious Diseases Unit, University Hospitals Leicester, and Department of Inflammation, Infection and Immunity, University of Leicester, Leicester, United Kingdom
    N Engl J Med 361:2424-35. 2009
  5. ncbi Response to a monovalent 2009 influenza A (H1N1) vaccine
    Michael E Greenberg
    Clinical Research and Development, CSL, Parkville, Vic, Australia
    N Engl J Med 361:2405-13. 2009
  6. pmc Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans
    Rebecca J Garten
    WHO Collaborating Center for Influenza, Centers for Disease Control and Prevention CDC, Atlanta, GA 30333, USA
    Science 325:197-201. 2009
  7. ncbi Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial
    Xiao Feng Liang
    Chinese Center for Disease Control and Prevention, Beijing, China
    Lancet 375:56-66. 2010
  8. ncbi Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children
    Steven Black
    Center for Global Health, University of Cincinnati Children s Hospital, Cincinnati, OH 45229, USA
    Pediatr Infect Dis J 30:1081-5. 2011
  9. pmc Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes
    Erica Spackman
    Southeast Poultry Research Laboratory, USDA Agricultural Research Service, Athens, Georgia 30605, USA
    J Clin Microbiol 40:3256-60. 2002
  10. pmc Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age
    Danuta M Skowronski
    British Columbia Centre for Disease Control, Vancouver, BC, V5Z 4R4, Canada
    J Infect Dis 203:158-67. 2011

Detail Information

Publications282 found, 100 shown here

  1. ncbi A novel influenza A (H1N1) vaccine in various age groups
    Feng Cai Zhu
    Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
    N Engl J Med 361:2414-23. 2009
    ..There is an urgent need for a vaccine that is effective against the 2009 pandemic influenza A (H1N1) virus...
  2. ncbi Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials
    Eric Plennevaux
    Clinical Development Department, Sanofi Pasteur, Lyon, France
    Lancet 375:41-8. 2010
    ..We therefore report preliminary safety and immunogenicity results after one injection of a licensed monovalent pandemic H1N1 vaccine in the USA...
  3. pmc Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls
    Ron A M Fouchier
    Dept of Virology, Erasmus Medical Center, P O Box 1738, 3000 DR Rotterdam, The Netherlands
    J Virol 79:2814-22. 2005
    ..We propose that sequence analyses of HA and NA genes of influenza A viruses be used for the rapid identification of existing and novel HA and NA subtypes...
  4. ncbi Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine
    Tristan W Clark
    Infectious Diseases Unit, University Hospitals Leicester, and Department of Inflammation, Infection and Immunity, University of Leicester, Leicester, United Kingdom
    N Engl J Med 361:2424-35. 2009
    ..The 2009 pandemic influenza A (H1N1) virus has emerged to cause the first pandemic of the 21st century. Development of effective vaccines is a public health priority...
  5. ncbi Response to a monovalent 2009 influenza A (H1N1) vaccine
    Michael E Greenberg
    Clinical Research and Development, CSL, Parkville, Vic, Australia
    N Engl J Med 361:2405-13. 2009
    ..A randomized, observer-blind, parallel-group trial evaluating two doses of an inactivated, split-virus 2009 H1N1 vaccine in healthy adults between the ages of 18 and 64 years is ongoing at a single site in Australia...
  6. pmc Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans
    Rebecca J Garten
    WHO Collaborating Center for Influenza, Centers for Disease Control and Prevention CDC, Atlanta, GA 30333, USA
    Science 325:197-201. 2009
    ..Antigenically the viruses are homogeneous and similar to North American swine A(H1N1) viruses but distinct from seasonal human A(H1N1)...
  7. ncbi Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial
    Xiao Feng Liang
    Chinese Center for Disease Control and Prevention, Beijing, China
    Lancet 375:56-66. 2010
    ..The current influenza pandemic calls for a safe and effective vaccine. We assessed the safety and immunogenicity of eight formulations of 2009 pandemic influenza A H1N1 vaccine produced by ten Chinese manufacturers...
  8. ncbi Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children
    Steven Black
    Center for Global Health, University of Cincinnati Children s Hospital, Cincinnati, OH 45229, USA
    Pediatr Infect Dis J 30:1081-5. 2011
    ..Neither seasonal nor challenge-based correlates have been evaluated in children...
  9. pmc Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes
    Erica Spackman
    Southeast Poultry Research Laboratory, USDA Agricultural Research Service, Athens, Georgia 30605, USA
    J Clin Microbiol 40:3256-60. 2002
    ..The remaining samples were positive with only one detection method. Overall the sensitivity and specificity of the H7- and H5-specific RRT-PCR were similar to those of VI and HI...
  10. pmc Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age
    Danuta M Skowronski
    British Columbia Centre for Disease Control, Vancouver, BC, V5Z 4R4, Canada
    J Infect Dis 203:158-67. 2011
    ..Pandemic H1N1 (pH1N1) surveillance data showed lower attack rates but higher risk of severe outcomes with advanced age. We explored immuno-epidemiologic correlates of surveillance findings including humoral and cell-mediated immunity (CMI)...
  11. ncbi Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults
    Tino F Schwarz
    Stiftung Juliusspital, Körperschaft des öffentlichen Rechts, Juliuspromenade 19, 97070 Wurzburg, Germany
    Vaccine 27:6284-90. 2009
    ....
  12. ncbi Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans?
    Regina Allwinn
    Institute of Medical Virology, University Hospital, Frankfurt M, Germany
    Med Microbiol Immunol 199:117-21. 2010
    ..Expecting the next waves of influenza A/H1N1v infections, HI testing may avoid vaccinations under special risk of severe or hidden adverse reactions...
  13. ncbi AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age
    Francois Roman
    GlaxoSmithKline Biologicals, Wavre
    Clin Infect Dis 51:668-77. 2010
    ..Vaccination of high-risk groups was started shortly after the emergence of the influenza A (H1N1)2009 pandemic virus...
  14. pmc Testing human sera for antibodies against avian influenza viruses: horse RBC hemagglutination inhibition vs. microneutralization assays
    Ghazi Kayali
    Center for Emerging Infectious Diseases, Department of Epidemiology, College of Public Health, University of Iowa, Oakdale Research Park, MTF B145, 2501 Crosspark Road, Coralville, IA 52241 8802, United States
    J Clin Virol 43:73-8. 2008
    ..Recent research suggests that the sensitivity of the HI assay can be improved by switching from the traditionally used turkey, guinea pig, human, or chicken RBCs to horse RBCs...
  15. ncbi Mapping the antigenic and genetic evolution of influenza virus
    Derek J Smith
    Department of Zoology, University of Cambridge, Downing Street, Cambridge CB2 3EJ, UK
    Science 305:371-6. 2004
    ..Further, this approach offers a route to predicting the relative success of emerging strains, which could be achieved by quantifying the combined effects of population level immune escape and viral fitness on strain evolution...
  16. ncbi Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection
    Suzanne E Ohmit
    Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA
    J Infect Dis 204:1879-85. 2011
    ..Questions have been raised about its use as a surrogate for vaccine efficacy, particularly with regard to an absolute titer indicating seroprotection...
  17. pmc Effect of vaccine use in the evolution of Mexican lineage H5N2 avian influenza virus
    Chang Won Lee
    Southeast Poultry Research Laboratory, US Department of Agriculture, Athens, GA 30605, USA
    J Virol 78:8372-81. 2004
    ....
  18. ncbi An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers
    Abdullah S Madhun
    Influenza Centre, The Gade Institute, University of Bergen, N 5021 Bergen, Norway
    Vaccine 29:266-73. 2010
    ..A rapid induction of protective antibody is important in reducing community spread of pandemic influenza and in helping maintain the integrity of the health care system during the pandemic...
  19. ncbi Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial
    Karl G Nicholson
    Infectious Diseases Unit, Vaccine Evaluation Centre, University Hospitals of Leicester NHS Trust and Department of Infection, Immunity, and Inflammation, University of Leicester, UK
    Lancet Infect Dis 11:91-101. 2011
    ..We assessed the safety and immunogenicity in adults in the UK of pandemic H1N1 whole-virion vaccine and oil-in-water adjuvanted vaccine purchased by the UK government in 2009...
  20. pmc Reemerging H5N1 influenza viruses in Hong Kong in 2002 are highly pathogenic to ducks
    Katharine M Sturm-Ramirez
    Division of Virology, Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    J Virol 78:4892-901. 2004
    ..This is the first reported case of lethal influenza virus infection in wild aquatic birds since 1961...
  21. ncbi A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart
    K G Nicholson
    Vaccine Evaluation Centre, University Hospitals of Leicester NHS Trust, Department of Inflammation, Infection and Immunity, University of Leicester, UK
    Health Technol Assess 14:193-334. 2010
    ....
  22. ncbi Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children
    Terry Nolan
    Melbourne School of Population Health, The University of Melbourne, Victoria, Australia
    Vaccine 26:6383-91. 2008
    ....
  23. ncbi Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study
    Isabel Leroux-Roels
    Center for Vaccinology, Ghent University and Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    Vaccine 28:849-57. 2010
    ..In contrast, priming without adjuvant appears to inhibit the response to subsequent vaccination with a heterologous strain. These findings should guide the development of vaccines to combat the present influenza A/H1N1 pandemic...
  24. ncbi Incidence of pandemic (H1N1) 2009 influenza infection in children and pregnant women during the 2009 influenza season in Western Australia - a seroprevalence study
    Gary K Dowse
    Communicable Disease Control Directorate, WA Health, Perth, WA, Australia
    Med J Aust 194:68-72. 2011
    ..To determine antibody levels and estimate incidence of infection with pandemic (H1N1) 2009 influenza in children and pregnant women during the 2009 winter in Western Australia...
  25. pmc Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults
    Nancy F Crum-Cianflone
    Infectious Disease Clinical Research Program, Uniformed Services University of Health Sciences, Bethesda, Maryland, USA
    Clin Infect Dis 52:138-46. 2011
    ..Limited data exist on the immunogenicity of the 2009 influenza A (H1N1) vaccine among immunocompromised persons, including those with human immunodeficiency virus (HIV) infection...
  26. ncbi Serological study of the 2009 pandemic due to influenza A H1N1 in the metropolitan French population
    J Delangue
    Unite des Virus Emergents, UMR190 Université Aix Marseille 2 and Institut de Recherche pour le Développement, Marseille, France
    Clin Microbiol Infect 18:177-83. 2012
    ....
  27. ncbi Cross-protection against homologous drift variants of influenza A and B after vaccination with split vaccine
    R Heckler
    Niedersächsisches Landesgesundheitsamt, Hannover, Germany
    Intervirology 50:58-62. 2007
    ..The results demonstrate that in situations where drift variants emerge too late to be included in the influenza vaccine formulation, the cross-protection conferred must be evaluated on a case-by-case basis...
  28. pmc A computational framework for influenza antigenic cartography
    Zhipeng Cai
    Department of Basic Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, Mississippi, USA
    PLoS Comput Biol 6:e1000949. 2010
    ..The webserver is available at http://sysbio.cvm.msstate.edu/AntigenMap...
  29. ncbi Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children
    Stan L Block
    Kentucky Pediatric and Adult Research, Bardstown, KY, USA
    Pediatr Infect Dis J 31:745-51. 2012
    ....
  30. ncbi Measurement of antibodies to avian influenza virus A(H7N7) in humans by hemagglutination inhibition test
    Adam Meijer
    Section Virology, Diagnostic Laboratory for Infectious Diseases and Screening, National Institute of Public Health and the Environment, PO Box 1, 3720 BA Bilthoven, The Netherlands
    J Virol Methods 132:113-20. 2006
    ..In conclusion, by applying an HI-test using horse erythrocytes human antibodies against the avian A(H7N7) virus were detected with high sensitivity and specificity in an unexpectedly high proportion of exposed persons...
  31. pmc Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults
    Nancy F Crum-Cianflone
    Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    Vaccine 29:3183-91. 2011
    ..Although vaccination against the H1N1 pandemic influenza strain is recommended, currently there are no data on the durability of post-vaccination antibody responses in this population...
  32. pmc Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans
    Daniela Frasca
    Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA
    Vaccine 28:8077-84. 2010
    ..These results could contribute to developing more effective vaccines to protect the elderly as well as identifying those most at risk...
  33. ncbi Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children
    Vladimir Gilca
    Quebec Public Health Institute, Canada
    Vaccine 30:35-41. 2011
    ..In 2009, several countries used the ASO3-adjuvanted pandemic A/H1N1 vaccine. We assessed the persistence of antibody and the priming induced by a single paediatric dose of this vaccine in children...
  34. ncbi Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study
    Cem Gabay
    University Hospitals of Geneva and University of Geneva, Geneva, Switzerland
    Arthritis Rheum 63:1486-96. 2011
    ..To identify the determinants of antibody responses to adjuvanted split influenza A (H1N1) vaccines in patients with inflammatory rheumatic diseases...
  35. pmc Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population
    Elisabeth Huijskens
    Laboratory of Medical Microbiology and Immunology, St Elisabeth Hospital, P O 747, 5000 AS Tilburg, Netherlands
    Clin Vaccine Immunol 18:1401-5. 2011
    ..More studies on the effect of yearly seasonal influenza virus vaccination on the immune response are warranted...
  36. pmc Immune protection induced on day 10 following administration of the 2009 A/H1N1 pandemic influenza vaccine
    Yizhuo Sun
    Key Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China
    PLoS ONE 5:e14270. 2010
    ..The kinetics of the immune response following vaccination with the 2009 A/H1N1 influenza vaccine need further investigation...
  37. pmc Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model
    Adrianus C M Boon
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    J Virol 84:7662-7. 2010
    ..Passive transfer of these antibodies prior to infection protected mice from H1N1pdm-induced pathogenicity, demonstrating the effectiveness of these cross-reactive neutralizing antibodies in vivo...
  38. pmc Influence of prior influenza vaccination on antibody and B-cell responses
    Sanae Sasaki
    Department of Medicine, Stanford University School of Medicine, Stanford, California, United States of America
    PLoS ONE 3:e2975. 2008
    ..In particular, prior year TIV vaccination is associated with sustained higher HAI titer one year later but lower antibody response to new LAIV or TIV vaccination, and a lower effector B-cell response to new TIV but not LAIV vaccination...
  39. ncbi Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant
    Murdo Ferguson
    Colchester Research Group, Truro, Nova Scotia, Canada
    J Infect Dis 205:733-44. 2012
    ..In this study (NCT00985088) we evaluated different formulations of an H1N1 2009 pandemic influenza vaccine that deliver various viral hemagglutinin (HA) doses with or without AS03 (a tocopherol-based oil-in-water adjuvant system)...
  40. pmc A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults
    Kawsar R Talaat
    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States
    Vaccine 27:3744-53. 2009
    ..Live attenuated influenza vaccines (LAIVs) are being developed and tested against a variety of influenza viruses with pandemic potential. We describe the results of an open-label Phase I trial of a live attenuated H7N3 virus vaccine...
  41. ncbi Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes
    Yixin Chen
    National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Key Laboratory of the Ministry of Education for Cell Biology and Tumor Cell Engineering, School of Life Sciences, Xiamen University, Xiamen, China
    J Infect Dis 199:49-58. 2009
    ....
  42. pmc Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus
    Jonathan A McCullers
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Infect Dis 50:1487-92. 2010
    ..Receipt of a vaccine to a related virus significantly enhanced the neutralization capacity of these responses, suggesting homologous vaccination against the 2009 pandemic H1N1 influenza virus would have a similar effect...
  43. pmc Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials
    Francois Roman
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Clin Vaccine Immunol 18:835-43. 2011
    ..Baseline A/H1N1/2009-specific CD4⁺ T-cell frequencies did not predict post-dose 1 antibody responses, but there was some correlation between post-dose 1 CD4⁺ T-cell frequencies and post-dose 2 antibody responses...
  44. ncbi A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine
    Rebecca J Cox
    Influenza Centre, The Gade Institute, University of Bergen, N 5021 Bergen, Norway
    Vaccine 27:1889-97. 2009
    ..In conclusion, our study shows that producing effective H7 pandemic vaccines is as challenging as has been observed for H5 vaccines...
  45. ncbi A plant-produced influenza subunit vaccine protects ferrets against virus challenge
    Vadim Mett
    Fraunhofer USA Center for Molecular Biotechnology, Newark, DE, USA
    Influenza Other Respir Viruses 2:33-40. 2008
    ....
  46. pmc Reproducibility of serologic assays for influenza virus A (H5N1)
    Iain Stephenson
    University of Leicester, UK
    Emerg Infect Dis 15:1252-9. 2009
    ..Sheep antiserum as a standard did not reliably reduce variability. The World Health Organization has established 07/150 as an international standard for antibody to clade 1 subtype H5 and has an assigned potency of 1,000 IU/ampoule...
  47. pmc Role of domestic ducks in the propagation and biological evolution of highly pathogenic H5N1 influenza viruses in Asia
    D J Hulse-Post
    Division of Virology, Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Proc Natl Acad Sci U S A 102:10682-7. 2005
    ..These results suggest that the duck has become the "Trojan horse" of Asian H5N1 influenza viruses. The ducks that are unaffected by infection with these viruses continue to circulate these viruses, presenting a pandemic threat...
  48. ncbi Serological reports of human infections of H7 and H9 avian influenza viruses in northern China
    Na Jia
    Beijing Institute of Microbiology and Epidemiology, Fengtai District, Beijing, PR China
    J Clin Virol 44:225-9. 2009
    ..H7 and H9 subtype avian influenza viruses pose a similar threat to humans as H5 virus...
  49. pmc Serological response to the 2009 pandemic influenza A (H1N1) virus for disease diagnosis and estimating the infection rate in Thai population
    Hatairat Lerdsamran
    Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
    PLoS ONE 6:e16164. 2011
    ..Individuals infected with the 2009 pandemic virus A(H1N1) developed serological response which can be measured by hemagglutination-inhibition (HI) and microneutralization (microNT) assays...
  50. ncbi Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection
    Laura Bungener
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen and University of Groningen, Postbus 30 001, 9700 RB Groningen, The Netherlands
    Vaccine 26:2350-9. 2008
    ..Major difference between these groups of mice was the type of immune response induced, TH2 instead of TH1, indicating that a TH1 response plays a major role in viral clearance...
  51. ncbi The immune response and maternal antibody interference to a heterologous H1N1 swine influenza virus infection following vaccination
    Pravina Kitikoon
    Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA
    Vet Immunol Immunopathol 112:117-28. 2006
    ..The results of this study question the effectiveness of the current practice of generating increased MDA levels through sow vaccination in protecting piglets against disease...
  52. ncbi Lung and salivary scavenger receptor glycoprotein-340 contribute to the host defense against influenza A viruses
    Kevan L Hartshorn
    Department of Medicine, Section of Hematology Oncology, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Am J Physiol Lung Cell Mol Physiol 285:L1066-76. 2003
    ..Furthermore, removal of gp-340 from BAL fluid and saliva significantly reduced anti-IAV activity. Hence, gp-340 contributes to defense against IAV and may be particularly relevant to defense against SP-D-resistant viral strains...
  53. pmc Emergence of an influenza B virus with antigenic change
    Naoko Nakagawa
    Department of Parasitic Agents, Kobe Institute of Health, 4 6, Minatojima Nakamachi, Japan
    J Clin Microbiol 40:3068-70. 2002
    ..The results of genetic analysis clarified that a point mutation of the nucleotide at position 126 in the HA1 region and the corresponding one-amino-acid substitution altered viral antigenicity...
  54. pmc Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses
    Bao Zhong Wang
    Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Road, Atlanta, Georgia 30322, USA
    J Virol 82:11813-23. 2008
    ..They also indicate that such cVLP vaccines are a promising new approach for protection against pandemic influenza viruses...
  55. ncbi Virological surveillance and preliminary antigenic characterization of influenza viruses in pigs in five European countries from 2006 to 2008
    C S Kyriakis
    Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
    Zoonoses Public Health 58:93-101. 2011
    ..However, antisera against human viruses isolated during the last decade did not react with currently circulating H1 or H3 SIVs, suggesting that especially young people may be, to some degree, susceptible to SIV infections...
  56. ncbi Fusion of HSP70 gene of Mycobacterium tuberculosis to hemagglutinin (H5) gene of avian influenza virus in DNA vaccine enhances its potency
    M Rasoli
    Institute of Biosciences, Universiti Putra Malaysia, Selangor, Malaysia
    Acta Virol 54:33-9. 2010
    ..However, the increase was not statistically significant. We have demonstrated for the first time that the H5 DNA vaccine with fused HSP70 gene may produce an enhanced induction of humoral immune response to AIV in chickens...
  57. ncbi A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults
    Stan L Block
    Kentucky Pediatric and Adult Research, 201 South 5th Street, Bardstown, KY 40004 1142, USA
    Vaccine 29:9391-7. 2011
    ..Quadrivalent live attenuated influenza vaccine (Q/LAIV) is an investigational 4-strain formulation of LAIV that contains 2 A strains, A/H1N1 and A/H3N2, and 2 B strains, 1 from each lineage...
  58. pmc Serologic evidence of H1 swine Influenza virus infection in swine farm residents and employees
    Christopher W Olsen
    University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    Emerg Infect Dis 8:814-9. 2002
    ..Because pigs can play a role in generating genetically novel influenza viruses, swine farmers may represent an important sentinel population to evaluate the emergence of new pandemic influenza viruses...
  59. ncbi A seroepidemiological study of pandemic A/H1N1(2009) influenza in a rural population of Mali
    O A Koita
    Laboratory of Applied Molecular Biology, Faculty of Science and Techniques, University of Bamako, Bamako, Mali
    Clin Microbiol Infect 18:976-81. 2012
    ....
  60. ncbi Presence of hemagglutination inhibition and neutralization antibodies to Japanese encephalitis virus in wild pigs on an offshore island in Singapore
    E ein See
    Defence Medical Research Institute, Defence Science and Technology Agency, 10 Medical Drive, Singapore 117597, Republic of Singapore
    Acta Trop 81:233-6. 2002
    ..Our results indicate that the wild pigs have been infected with JEV on the offshore island and there is JEV transmission...
  61. ncbi Monoclonal antibody-based ELISA for detection of antibodies against H5 avian influenza viruses
    Ana Moreno
    Istituto Zooprofilattico Sperimentale della Lombardia e dell Emilia Romagna, Via Bianchi 9, 25124 Brescia, Italy
    J Virol Methods 187:424-30. 2013
    ....
  62. pmc Prevalence of antibodies against avian influenza A (H5N1) virus among Cullers and poultry workers in Ho Chi Minh City, 2005
    Constance Schultsz
    Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
    PLoS ONE 4:e7948. 2009
    ..We studied the prevalence of antibodies against H5N1 in poultry workers and cullers who were active in the program in Ho Chi Minh City in 2004 and 2005...
  63. ncbi Serologic evidence of avian influenza H9N2 and paramyxovirus type 1 infection in emus (Dromaius novaehollandiae) in India
    Prashant V Shinde
    Avian Influenza Group, National Institute of Virology Microbial Containment Complex, 131 1, Sus Road, Pashan, Pune 411 021, India
    Avian Dis 56:257-60. 2012
    ..Performance of both HI and MN assays was similar, suggesting the utility of using the MN assay along with HI assay for surveillance studies. This is the first report of the seroprevalence of AI H9N2 and APMV-1 in emus in India...
  64. ncbi Interactions of Pseudomonas aeruginosa PA-IIL lectin with quail egg white glycoproteins
    B Lerrer
    Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel
    Can J Microbiol 47:1095-100. 2001
    ....
  65. ncbi Specific antibody response after influenza immunization in systemic lupus erythematosus
    Mahmoud Abu-Shakra
    Department of Medicine, Soroka Medical Center and Ben Gurion University, Tel Hashomer, Israel
    J Rheumatol 29:2555-7. 2002
    ..To determine the efficacy of influenza virus vaccine in patients with systemic lupus erythematosus (SLE)...
  66. ncbi On the bias in HI titers and how to reduce it
    Jozef J P Nauta
    Solvay Pharmaceuticals, Clinical Development Influenza Vaccines, P O Box 900, 1380 DA Weesp, The Netherlands
    Vaccine 24:6645-6. 2006
    ..A new definition is proposed, the mid-value definition. Under mild conditions mid-value titers are on average closer to the true value than standard titers...
  67. ncbi Serological evidence of pig-to-human influenza virus transmission on Thai swine farms
    Pravina Kitikoon
    Faculty of Veterinary Science, Chulalongkorn University, Henri Dunant Rd, Bangkok 10330, Thailand
    Vet Microbiol 148:413-8. 2011
    ..63, 95% CI, 14.65-124) and swH1N2 (OR 58, 95% CI, 13.12-256.3) viruses. No evidence of human-to-pig influenza virus transmission was detected in this study...
  68. ncbi Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies
    A Horvath
    Department of Immunology, L Eotvos University, God, Hungary
    Antiviral Res 52:43-53. 2001
    ..The data provide evidence of the potential of intranasally administered SAP for prophylactic treatment of influenza A virus infections in humans...
  69. ncbi Cross-reacting antibodies against the pandemic (H1N1) 2009 influenza virus in older Australians
    Robert Booy
    National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children s Hospital at Westmead, Sydney, NSW, Australia
    Med J Aust 194:19-23. 2011
    ..To assess background pre-pandemic cross-reacting antibodies to the pandemic (H1N1) 2009 virus in older populations in Australia...
  70. ncbi Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial
    P Noel Barrett
    Global Research and Development, Baxter BioScience, Biomedical Research Centre, Orth Donau, Austria
    Lancet 377:751-9. 2011
    ..We investigated the safety, immunogenicity, and protective efficacy of a Vero-cell-culture-derived influenza vaccine, and assessed the correlation between vaccine efficacy and haemagglutination inhibition antibody titre...
  71. ncbi Eliminating bias in the estimation of the geometric mean of HI titres
    Jozef J P Nauta
    Clinical Development Influenza Vaccines, Solvay Pharmaceuticals, P O Box 900, NL 1380 DA Weesp, The Netherlands
    Biologicals 34:183-6. 2006
    ..The maximum likelihood estimate of the GMT of truncated HI titres can be readily obtained using the statistical software package SAS...
  72. pmc Early adaptive humoral immune responses and virus clearance in humans recently infected with pandemic 2009 H1N1 influenza virus
    Chao Qiu
    Shanghai Public Health Clinical Center, Institutes of Biomedical Sciences, Fudan University, Shanghai, China
    PLoS ONE 6:e22603. 2011
    ..These findings provide new important insights on the human immunity to natural influenza infection...
  73. ncbi Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents
    Chun Yi Lu
    Department of Pediatrics, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
    Vaccine 28:5864-70. 2010
    ..3% of adolescents aged 10-17 years generated protective antibodies. A second vaccination given 3 weeks later induced protective antibodies in 89.4% of all age groups. No severe adverse effects were found 6 weeks after vaccination...
  74. pmc Serological analysis of human pandemic influenza (H1N1) in Thailand
    Slinporn Prachayangprecha
    Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    J Health Popul Nutr 28:537-44. 2010
    ..Finally, the serological data might be useful for outbreak-prevention and control strategies and for the management of vaccination for the pandemic (H1N1) 2009 in Thailand...
  75. ncbi Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination
    Heimo Lagler
    Division of Infectious Diseases and Tropical Medicine, Department of Medicine 1, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Vaccine 29:6888-93. 2011
    ..Our results show that the novel vero cell derived and adjuvant-free pandemic A/California/07/2009 (H1N1) influenza vaccine induced limited but measurable immune responses in adult recipients of solid organ transplants...
  76. pmc Detection of Japanese encephalitis virus immunoglobulin M antibodies in serum by antibody capture radioimmunoassay
    D S Burke
    J Clin Microbiol 15:353-61. 1982
    ..The JE IgM ACRIA technique permits a rapid, accurate diagnosis of acute JE virus infections in both patients with and those without previous exposure to other flaviviruses...
  77. ncbi The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis
    Ori Elkayam
    Department of Rheumatology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Semin Arthritis Rheum 39:442-7. 2010
    ..To assess the effect of the timing of vaccination in relation to administration of infliximab on the efficacy and safety of influenza vaccine in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS)...
  78. pmc A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults
    Hideaki Nagai
    National Hospital Organization Tokyo National Hospital, 3 1 1, Takeoka, Kiyose City, Tokyo 204 8585, Japan
    BMC Infect Dis 10:338. 2010
    ..This study therefore aimed to assess the immunogenicity and tolerability of a prepandemic (H5N1) influenza vaccine adjuvanted with AS03A in Japanese adults...
  79. pmc Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults
    Wendy A Keitel
    Baylor College of Medicine Vaccine Research Center, Houston, TX 77030, USA
    Vaccine 27:6642-8. 2009
    ..Because influenza antibody titers vary significantly between different laboratories, international standardization of assays is warranted...
  80. ncbi Seasonal influenza vaccine and increased risk of pandemic A/H1N1‐related illness: first detection of the association in British Columbia, Canada
    Naveed Z Janjua
    BC Centre for Disease Control, Health Canada, Vancouver, Canada
    Clin Infect Dis 51:1017-27. 2010
    ..During the outbreak investigation, we explored the relationship between prior receipt of trivalent inactivated influenza vaccine (TIV) and pH1N1-related illness...
  81. ncbi Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico
    Constantino López-Macías
    Medical Research Unit on Immunochemistry, Specialities Hospital of the National Medical Centre Siglo XXI Mexican Social Security Institute IMSS, Mexico City, Mexico
    Vaccine 29:7826-34. 2011
    ..Based on these data, additional clinical trials are in development to evaluate influenza vaccine candidate antigens manufactured using Spodoptera frugiperda (Sf9)/baculovirus-based VLP technology...
  82. ncbi Influenza Β/Victoria antigen induces strong recall of Β/Yamagata but lower Β/Victoria response in children primed with two doses of Β/Yamagata
    Danuta M Skowronski
    British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
    Pediatr Infect Dis J 30:833-9. 2011
    ..Trivalent inactivated influenza vaccine (TIV) contains 1 of 2 influenza B/lineages (B/Yamagata or B/Victoria) annually. We assessed prime-boost responses in young children following a change in the B/lineage included in TIV...
  83. pmc Utility of pandemic H1N1 2009 influenza virus recombinant hemagglutinin protein-based enzyme-linked immunosorbent assay for serosurveillance
    V A Arankalle
    Hepatitis Division, National Institute of Virology, Pashan, Pune 411021, India
    Clin Vaccine Immunol 17:1481-3. 2010
    ..The results showed a concordance of 98.4%, suggesting the utility of the ELISA in serosurveillance. Two hundred sixty-nine (100%) serum samples with an HI titer of > or =20 were ELISA reactive...
  84. ncbi Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children
    David W Scheifele
    Vaccine Evaluation Center, BC Children s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Pediatr Infect Dis J 30:402-7. 2011
    ..When Canada chose an adjuvanted influenza A H1N1(2009) vaccine for pandemic control, dosing requirements and safety in children were unknown. This study compared responses after 1 and 2 doses in young children...
  85. ncbi Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers
    A M Iorio
    Department of Medical Surgery Specialities and Public Health, University of Perugia, Perugia, Italy
    Gerontology 53:411-8. 2007
    ..Concern about the possibility that annually repeated influenza immunizationmayinduce a lower antibody response than first vaccination...
  86. ncbi Induction of cross-neutralizing antibody against H5N1 virus after vaccination with seasonal influenza vaccine in COPD patients
    Uraiwan Kositanont
    Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
    Viral Immunol 23:329-34. 2010
    ....
  87. pmc Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan
    Makoto Ujike
    National Institute of Infectious Diseases, Musashi Murayama, Tokyo, Japan
    Emerg Infect Dis 16:926-35. 2010
    ..Our data indicate that the current vaccine or zanamivir and amantadine are effective against recent ORVs, but continuous surveillance remains necessary...
  88. pmc Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009
    Vernon J Lee
    Biodefence Centre, Ministry of Defence, Transit Road, Singapore 778910, Singapore
    BMC Infect Dis 10:164. 2010
    ..Anti-viral prophylaxis is used to prevent the transmission of influenza. We studied serological confirmation of 2009 Influenza A (H1N1) infections during oseltamivir prophylaxis and after cessation of prophylaxis...
  89. ncbi Potential infections of H5N1 and H9N2 avian influenza do exist in Guangdong populations of China
    Ci Yong Lu
    School of Public Health, Sun Yat Sen University, Guangzhou, Guangdong 510080, China
    Chin Med J (Engl) 121:2050-3. 2008
    ....
  90. ncbi Serological profiles after consecutive experimental infections of pigs with European H1N1, H3N2, and H1N2 swine influenza viruses
    Kristien Van Reeth
    Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
    Viral Immunol 19:373-82. 2006
    ..In conclusion, the HI test remains adequate for the differential diagnosis of infections with H1N1, H3N2, and H1N2 in European swine populations if it is properly used and if the SIV vaccination status is taken into account...
  91. ncbi A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials
    Thierry Boge
    Centre Hospitalier de Bourg en Bresse, 01012 Bourg en Bresse, France
    Vaccine 27:5677-84. 2009
    ..Influenza vaccination is recommended for the elderly in many countries, but immune responses are weaker compared to younger adults...
  92. pmc Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine among pregnant women: lowered antibody response by prior seasonal vaccination
    Satoko Ohfuji
    Department of Public Health, Osaka City University Graduate School of Medicine, Osaka City Juso Hospital, Japan
    J Infect Dis 203:1301-8. 2011
    ..Pregnant women are a high-risk group for influenza-associated complications and hospitalizations...
  93. ncbi Description of the outbreak of equine influenza (H3N8) in the United Kingdom in 2003, during which recently vaccinated horses in Newmarket developed respiratory disease
    J R Newton
    Centre for Preventive Medicine, Animal Health Trust, Lanwades Park, Kentford, Newmarket, Suffolk CB8 7UU
    Vet Rec 158:185-92. 2006
    ....
  94. ncbi Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients
    Oriol Manuel
    Transplantation Center, Infectious Diseases Service, University Hospital of Lausanne CHUV and University of Lausanne, Switzerland
    Clin Infect Dis 52:248-56. 2011
    ..We evaluated the humoral response to the influenza A H1N1/09 vaccine in solid-organ transplant (SOT) recipients, in patients with human immunodeficiency virus (HIV) infection, and in healthy individuals...
  95. ncbi Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans
    Jiang Wu
    Beijing Centre for Disease Control and Prevention, China
    Vaccine 29:1009-16. 2011
    ..MN and ELISPOT assays showed a similar effect. Vaccination with pandemic H1N1 vaccine first is recommended to avoid an associated inhibitory effect by the seasonal trivalent flu vaccine...
  96. ncbi Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations
    Karl G Nicholson
    Infectious Diseases Unit, University Hospitals Leicester, Leicester, LE1 5WW, UK
    Vaccine 28:171-8. 2009
    ..However, no vaccine formulation satisfied all European regulatory criteria for pandemic vaccines...
  97. ncbi Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial
    Terry Nolan
    Vaccine and Immunization Research Group, School of Population Health, University of Melbourne, and Murdoch Children s Research Institute, Victoria, Australia
    JAMA 303:37-46. 2010
    ..In the ongoing influenza pandemic, a safe and effective vaccine against 2009 influenza A(H1N1) is needed for infants and children...
  98. ncbi Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period
    Caterina Rizzo
    National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanità Rome, Viale Regina Elena 299, Rome, Italy
    Vaccine 28:3558-62. 2010
    ..5%, 19.2%, and 58.2%, respectively. The results suggest that the Italian population was not fully naïf to the current pandemic virus and that the possible previous exposure and immune response increases with age...
  99. ncbi Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses
    Filippo Ansaldi
    CIRI IV, Department of Health Sciences, University of Genoa, Genoa, Italy
    Vaccine 26:1525-9. 2008
    ..Thus, MF59-adjuvanted vaccine confers greater immunogenicity than non-adjuvanted vaccines in vulnerable populations...
  100. pmc Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine
    Daniela Frasca
    Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA
    Int Immunol 24:175-82. 2012
    ....
  101. ncbi Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines
    Nick J Andrews
    Department of Statistics, Modelling and Economics, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, UK
    Vaccine 29:7913-9. 2011
    ..Reduction in the interval between doses for earlier protection would be at the cost of reduced immunogenicity. The effect of seasonal vaccine on immunogenicity merits further investigation...

Research Grants23

  1. SIMULTANEOUS SCREENING FOR A/H3N2, A/H1N1, A/H5N1 AND B INFLUENZA VIRUSES
    Erica Dawson; Fiscal Year: 2009
    ....
  2. ENHANCING COLLECTIN MEDIATED HOST DEFENSE
    Kevan Hartshorn; Fiscal Year: 2001
    ..These experiments should yield important insights into basic collection biology and demonstrate that enhancement of collectin-mediated pulmonary host defense can be achieved in vivo through rational alteration of wild type collectins. ..
  3. Neonatal Immunization with Acellular Pertussis Vaccines
    Natasha Halasa; Fiscal Year: 2007
    ....
  4. Treatment of Acute Hepatitis C in Injection Drug Users
    Anna Wald; Fiscal Year: 2005
    ..abstract_text> ..
  5. ECOLOGY AND GENETICS OF VENEZUELAN EQUINE ENCEPHALITIS
    Scott Weaver; Fiscal Year: 2005
    ..This information will be invaluable in targeting prevention and control resources, especially for obtaining maximum benefit in developing countries with limited resources. ..
  6. COMBINATION CHEMOTHERAPY FOR PANDEMIC INFLUENZA
    Robert Webster; Fiscal Year: 2005
    ....
  7. Investigation of influenza virulence mediated by the NS1A protein
    DIANA NOAH; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  8. TRYPANOSOMA CRUZI MUCOSAL & SYSTEMIC PROTECTIVE IMMUNITY
    DANIEL HOFT; Fiscal Year: 2008
    ..Chemokine and/or integrin receptor expression will be studied by flow cytometry and RT-Real-Time PCR, and the in vivo effects of defective chemokine and integrin binding and/or signaling will be evaluated. [unreadable] [unreadable]..
  9. 14th International CHRO Workshop
    Irving Nachamkin; Fiscal Year: 2007
    ..abstract_text> ..
  10. Host range restriction of human influenza viruses
    Christopher Olsen; Fiscal Year: 2009
    ..abstract_text> ..
  11. West Nile Virus Life Cycle in Flavivirus-Resistant Cells
    Pei Yong Shi; Fiscal Year: 2006
    ..abstract_text> ..
  12. A Novel Genetic Therapy for Herpes Keratitis
    JOHN KRIESEL; Fiscal Year: 2006
    ..An ex vivo model of HSV-1 reactivation in explanted mouse trigeminal ganglia is proposed as an efficient means for determining effective strategies for the delay or inhibition of reactivation. ..
  13. 13th International Campylobacter/Helicobacter workshop
    Irving Nachamkin; Fiscal Year: 2005
    ..abstract_text> ..
  14. Biodefense vaccine for pandemic influenza
    Lawrence Smith; Fiscal Year: 2005
    ..FINAL MILESTONE 3: Completion of Aim 2 and completion of IND ..
  15. 3rd Orthomyxoviruses Research Conference
    Jonathan McCullers; Fiscal Year: 2005
    ..The purpose of this proposal is to provide funds that will allow promising young investigators to interact with their peers and develop a commitment to this area of research. ..
  16. Development of a DNA Vaccine Against Influenza Virus
    Lawrence Smith; Fiscal Year: 2005
    ..These efforts are designed to be completed within 1 year in a manner that will generate an influenza DNA vaccine that can be manufactured for long-term stockpile. ..
  17. Vaccine Induced Mucosal Protection Against TB Infection
    DANIEL HOFT; Fiscal Year: 2005
    ..Prime/boosting strategies found to prevent BCG infection after aerosol challenges will be studied for the ability to prevent infection with virulent M. tuberculosis by aerosol challenge. ..
  18. Influenza-pneumococcal synergism: role of neuraminidase
    Jonathan McCullers; Fiscal Year: 2004
    ....
  19. 2nd Orthomyxoviruses Research Conference
    Jonathan McCullers; Fiscal Year: 2003
    ..The purpose of this proposal is to provide funds that will allow promising young investigators to interact with their peers and develop a commitment to this area of research. ..
  20. Lethal synergism between influenza and pneumococcus
    Jonathan McCullers; Fiscal Year: 2003
    ....
  21. IL-6 IN HERPES SIMPLEX VIRUS TYPE 1 OCULAR REACTIVATION
    JOHN KRIESEL; Fiscal Year: 2002
    ..Novel and specific viral mutants will be constructed based on the results of HSV-DNA binding and transient expression assays. ..
  22. Synergism Between Influenza Virus and Pneumococcus
    Jonathan McCullers; Fiscal Year: 2009
    ....